Literature DB >> 17347554

Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases.

Nilgun Araz1, Vahap Okan, Mustafa Demirci, Mustafa Araz.   

Abstract

Cholelithiasis rarely occurs in childhood. Ceftriaxone is a widely used antimicrobial agent in pediatrics due to the broad spectrum. Reversible biliary sludge and/or lithiasis, named as pseudolithiasis, have been reported in patients treated with ceftriaxone. We observed ceftriaxone-associated pseudolithiasis in 8 patients with meningitis. The aim of this study was to report the clinical characteristics of these patients and to evaluate the related factors for the development of ceftriaxone-associated pseudolithiasis in children. The study group consisted of 7 boys and 1 girl. All patients received ceftriaxone 100 mg/kg/day for meningitis. The ultrasonographic evaluation was performed on 5th-10th days after the initiation of the therapy. Biliary sludge was detected in one patient, and gallstone was detected in three patients, while biliary sludge with gallstone was detected in four patients. Six of the cases were diagnosed during summer time. Thus, high temperature may cause loss of fluid, leading to easier formation of sludge. Ceftriaxone treatment was discontinued after sonographic demonstration of pseudolithiasis. Gallbladder sonograms were found to be normal in all patients at the follow-up sonographic examinations performed after 30 days of the diagnosis without specific treatment. Clinicians should screen all pediatric patients living in areas with high temperature and receiving ceftriaxone treatment (over 100 mg/kg) by ultrasonography for biliary sludge or gallstone formation even if they are asymptomatic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347554     DOI: 10.1620/tjem.211.285

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  7 in total

Review 1.  Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.

Authors:  Yifan Zhang; Benxiang Ning; Huaijun Zhu; Xiaoming Cong; Leqing Zhou; Qiang Wang; Liming Zhang; Xizhao Sun
Journal:  Int Urol Nephrol       Date:  2016-04-28       Impact factor: 2.370

2.  Marked Direct Hyperbilirubinemia due to Ceftriaxone in an Adult with Sickle Cell Disease.

Authors:  Daniyeh Khurram; Leonid Shamban; Robert Kornas; Maryann Paul
Journal:  Case Rep Gastrointest Med       Date:  2015-05-25

3.  A case of ceftriaxone-associated biliary pseudolithiasis in an elderly patient with renal dysfunction.

Authors:  Shuichi Abe
Journal:  IDCases       Date:  2017-06-27

4.  Ceftriaxone-associated nephrolithiasis and gallstone in adults.

Authors:  Ghodsiyeh Azarkar; Motahare Mahi Birjand; Alireza Ehsanbakhsh; Bita Bijari; Mohammad Reza Abedini; Masood Ziaee
Journal:  Drug Healthc Patient Saf       Date:  2018-12-12

5.  Rapid Onset of Ceftriaxone-Induced Cholelithiasis in an Adult Patient.

Authors:  Hani Abdelaziz; Nancy Cormier; Tania Levesque; Jean St-Yves; Muhanad Al Habash; Oscar Diaz; Marie-Pierre Haberer; Dariu Calugaroiu; Mohamed Nashed
Journal:  J Glob Infect Dis       Date:  2022-02-16

6.  Ceftriaxone-associated nephrolithiasis in children.

Authors:  Azita Fesharakinia; Ali-Reza Ehsanbakhsh; Nasrin Ghorashadizadeh
Journal:  Iran J Pediatr       Date:  2013-12       Impact factor: 0.364

7.  Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections.

Authors:  Setsuki Tsukagoshi; Kunihiko Ishizawa; Kimitoshi Hirayanagi; Shun Nagamine; Kouki Makioka; Yukio Fujita; Yoshio Ikeda
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.